Royal Bank Of Canada started coverage on shares of Ra Pharmctl Inc (NASDAQ:RARX) in a report issued on Thursday, The Fly reports. The firm set an “outperform” rating on the stock.

Several other equities research analysts have also weighed in on RARX. Jefferies Group LLC set a $25.00 price objective on Ra Pharmctl and gave the stock a “buy” rating in a report on Friday, August 25th. Zacks Investment Research raised Ra Pharmctl from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Saturday, May 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Ra Pharmctl presently has a consensus rating of “Buy” and an average price target of $27.00.

Shares of Ra Pharmctl (RARX) traded up 5.84% during trading on Thursday, reaching $14.87. 119,396 shares of the company were exchanged. Ra Pharmctl has a one year low of $12.05 and a one year high of $24.12. The firm’s 50 day moving average price is $14.25 and its 200 day moving average price is $18.93. The company’s market capitalization is $336.20 million.

Ra Pharmctl (NASDAQ:RARX) last released its earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.06). Equities research analysts forecast that Ra Pharmctl will post ($2.33) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/14/ra-pharmctl-inc-rarx-research-coverage-started-at-royal-bank-of-canada.html.

In other news, major shareholder Bioventures Ltd Novartis sold 56,420 shares of the stock in a transaction on Monday, June 19th. The stock was sold at an average price of $21.29, for a total value of $1,201,181.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 14.50% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its holdings in Ra Pharmctl by 30.6% in the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after acquiring an additional 2,543 shares during the period. TIAA CREF Investment Management LLC raised its stake in shares of Ra Pharmctl by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock worth $167,000 after buying an additional 3,859 shares during the period. California State Teachers Retirement System raised its stake in shares of Ra Pharmctl by 26.1% in the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $390,000 after buying an additional 4,300 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Ra Pharmctl by 7.0% in the second quarter. Goldman Sachs Group Inc. now owns 73,103 shares of the company’s stock worth $1,370,000 after buying an additional 4,751 shares during the period. Finally, American International Group Inc. bought a new position in shares of Ra Pharmctl in the first quarter worth about $102,000. 66.26% of the stock is currently owned by institutional investors.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

The Fly

Analyst Recommendations for Ra Pharmctl (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.